Literature DB >> 22034029

AAV-mediated liver-directed gene therapy.

Mark S Sands1.   

Abstract

The liver is directly or indirectly involved in many essential processes and is affected by numerous inherited diseases. Therefore, many inherited diseases could be effectively treated by targeting the liver using gene transfer approaches. The challenges associated with liver-directed gene therapy are efficient targeting of hepatocytes, stability of the vector genome, and persistent high level expression. Many of these obstacles can be overcome with adeno-associated viral (AAV) gene transfer vectors. The first AAV gene transfer -vector developed for in vivo use was based on the AAV2 serotype. AAV2 has a broad tropism and transduces many cell types, including hepatocytes, relatively efficiently in vivo. The capsid protein confers the serological profile and at least 12 primate AAV serotypes have already been characterized. Importantly, pseudotyping a recombinant AAV vector with different capsid proteins can dramatically alter the tropism. Both AAV8 and AAV9 have higher affinities for hepatocytes when compared to AAV2. In particular, AAV8 can transduce three- to fourfold more hepatocytes and deliver three- to fourfold more genomes per transduced cell when compared to AAV2. Depending on the dose, AAV8 can transduce up to 90-95% of hepatocytes in the mouse liver following intraportal vein injection. Interestingly, comparable levels of transduction can be achieved following intravenous injection. Direct intraparenchymal injection of an AAV vector also mediates relatively high level long term expression. Additional specificity can be conferred by using liver-specific promoters in conjunction with AAV8 capsid proteins. In addition to treating primary hepatocyte defects, immune reactions to transgene products can be minimized by circumventing the fixed tissue macrophages of the liver, Kupffer cells, and limiting expression to hepatocytes. The ability to target hepatocytes by virtue of the AAV serotype and the use of liver-specific promoters allows investigators to test novel therapeutic approaches and answer basic clinical and biological questions.

Entities:  

Mesh:

Year:  2011        PMID: 22034029      PMCID: PMC4118577          DOI: 10.1007/978-1-61779-370-7_6

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  30 in total

1.  Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.

Authors:  H Nakai; S R Yant; T A Storm; S Fuess; L Meuse; M A Kay
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer.

Authors:  T M Daly; K K Ohlemiller; M S Roberts; C A Vogler; M S Sands
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

3.  Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors.

Authors:  A Donsante; C Vogler; N Muzyczka; J M Crawford; J Barker; T Flotte; M Campbell-Thompson; T Daly; M S Sands
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

4.  Transgene produces massive overexpression of human beta -glucuronidase in mice, lysosomal storage of enzyme, and strain-dependent tumors.

Authors:  Carole Vogler; Nancy Galvin; Beth Levy; Jeffery Grubb; Jinxing Jiang; Xiao Yan Zhou; William S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-18       Impact factor: 11.205

5.  Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse.

Authors:  Thomas J Sferra; Kristin Backstrom; Chuansong Wang; Rachel Rennard; Matt Miller; Yan Hu
Journal:  Mol Ther       Date:  2004-09       Impact factor: 11.454

6.  Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system.

Authors:  Corinna Burger; Oleg S Gorbatyuk; Margaret J Velardo; Carmen S Peden; Philip Williams; Sergei Zolotukhin; Paul J Reier; Ronald J Mandel; Nicholas Muzyczka
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

7.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

8.  Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.

Authors:  Stefan Stein; Marion G Ott; Stephan Schultze-Strasser; Anna Jauch; Barbara Burwinkel; Andrea Kinner; Manfred Schmidt; Alwin Krämer; Joachim Schwäble; Hanno Glimm; Ulrike Koehl; Carolin Preiss; Claudia Ball; Hans Martin; Gudrun Göhring; Kerstin Schwarzwaelder; Wolf-Karsten Hofmann; Kadin Karakaya; Sandrine Tchatchou; Rongxi Yang; Petra Reinecke; Klaus Kühlcke; Brigitte Schlegelberger; Adrian J Thrasher; Dieter Hoelzer; Reinhard Seger; Christof von Kalle; Manuel Grez
Journal:  Nat Med       Date:  2010-01-24       Impact factor: 53.440

9.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.

Authors:  Guang-Ping Gao; Mauricio R Alvira; Lili Wang; Roberto Calcedo; Julie Johnston; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

10.  Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system.

Authors:  B L Davidson; C S Stein; J A Heth; I Martins; R M Kotin; T A Derksen; J Zabner; A Ghodsi; J A Chiorini
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  35 in total

1.  Hepatic miR-181b-5p Contributes to Glycogen Synthesis Through Targeting EGR1.

Authors:  Shuyue Wang; Chen Liang; Huihan Ai; Meiting Yang; Jingwen Yi; Lei Liu; Zhenbo Song; Yongli Bao; Yuxin Li; Luguo Sun; Huiying Zhao
Journal:  Dig Dis Sci       Date:  2019-01-09       Impact factor: 3.199

2.  High-Throughput Quantification of In Vivo Adeno-Associated Virus Transduction with Barcoded Non-Coding RNAs.

Authors:  Meiyu Xu; Jia Li; Jun Xie; Ran He; Qin Su; Guangping Gao; Phillip W L Tai
Journal:  Hum Gene Ther       Date:  2019-06-17       Impact factor: 5.695

3.  Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors.

Authors:  Jun Mimuro; Hiroaki Mizukami; Shuji Hishikawa; Tomokazu Ikemoto; Akira Ishiwata; Asuka Sakata; Tsukasa Ohmori; Seiji Madoiwa; Fumiko Ono; Keiya Ozawa; Yoichi Sakata
Journal:  Mol Ther       Date:  2012-12-18       Impact factor: 11.454

4.  Taste Receptor Cells in Mice Express Receptors for the Hormone Adiponectin.

Authors:  Sean M Crosson; Andrew Marques; Peter Dib; Cedrick D Dotson; Steven D Munger; Sergei Zolotukhin
Journal:  Chem Senses       Date:  2019-07-17       Impact factor: 3.160

Review 5.  Liver induced transgene tolerance with AAV vectors.

Authors:  Geoffrey D Keeler; David M Markusic; Brad E Hoffman
Journal:  Cell Immunol       Date:  2017-12-05       Impact factor: 4.868

Review 6.  Immunomodulatory, liver depot gene therapy for Pompe disease.

Authors:  J E Bond; P S Kishnani; D D Koeberl
Journal:  Cell Immunol       Date:  2017-12-29       Impact factor: 4.868

7.  Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants.

Authors:  Damien Marsic; Lakshmanan Govindasamy; Seth Currlin; David M Markusic; Yu-Shan Tseng; Roland W Herzog; Mavis Agbandje-McKenna; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2014-07-22       Impact factor: 11.454

8.  Adeno-Associated Virus-Mediated Gene Transfer of Tissue Inhibitor of Metalloproteinases-1 Impairs Neutrophil Extracellular Trap Formation and Ameliorates Hepatic Ischemia and Reperfusion Injury.

Authors:  Sergio Duarte; Patrick Matian; Stacy Ma; Ronald W Busuttil; Ana J Coito
Journal:  Am J Pathol       Date:  2018-06-02       Impact factor: 4.307

9.  Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer.

Authors:  Hongfei Fang; Ngai Chin Lai; Mei Hua Gao; Atsushi Miyanohara; David M Roth; Tong Tang; H Kirk Hammond
Journal:  Hum Gene Ther Methods       Date:  2012-08       Impact factor: 2.396

10.  Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia.

Authors:  Sadik H Kassim; Hui Li; Peter Bell; Suryanarayan Somanathan; William Lagor; Frank Jacobs; Jeffrey Billheimer; James M Wilson; Daniel J Rader
Journal:  Hum Gene Ther       Date:  2012-11-14       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.